These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Plasma NfL levels and longitudinal change rates in Saracino D; Dorgham K; Camuzat A; Rinaldi D; Rametti-Lacroux A; Houot M; Clot F; Martin-Hardy P; Jornea L; Azuar C; Migliaccio R; Pasquier F; Couratier P; Auriacombe S; Sauvée M; Boutoleau-Bretonnière C; Pariente J; Didic M; Hannequin D; Wallon D; ; ; Colliot O; Dubois B; Brice A; Levy R; Forlani S; Le Ber I J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1278-1288. PubMed ID: 34349004 [TBL] [Abstract][Full Text] [Related]
29. Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson's disease. Zhu Y; Yang B; Wang F; Liu B; Li K; Yin K; Yin WF; Zhou C; Tian S; Ren H; Pang A; Yang X J Neuroimmunol; 2021 Sep; 358():577662. PubMed ID: 34311152 [TBL] [Abstract][Full Text] [Related]
30. Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression. Rabl M; Zullo L; Lewczuk P; Kornhuber J; Karikari TK; Blennow K; Zetterberg H; Bavato F; Quednow BB; Seifritz E; von Gunten A; Clark C; Popp J Alzheimers Res Ther; 2024 Jul; 16(1):165. PubMed ID: 39054505 [TBL] [Abstract][Full Text] [Related]
31. Serum neurofilament light chain: No clear relation to cognition and neuropsychiatric symptoms in stable MS. Aktas O; Renner A; Huss A; Filser M; Baetge S; Stute N; Gasis M; Lepka K; Goebels N; Senel M; Graf J; Enzinger C; Pinter D; Antoch G; Turowski B; Hartung HP; Albrecht P; Otto M; Tumani H; Penner IK Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32972970 [TBL] [Abstract][Full Text] [Related]
32. Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Lin YS; Lee WJ; Wang SJ; Fuh JL Sci Rep; 2018 Nov; 8(1):17368. PubMed ID: 30478269 [TBL] [Abstract][Full Text] [Related]
33. Potential role of neurofilament in COVID-19 and preeclampsia. Samara A; Herlenius E; O' Brien P; Khalil A Cell Rep Med; 2022 Jan; 3(1):100490. PubMed ID: 35103255 [TBL] [Abstract][Full Text] [Related]
34. Biomarkers of Neurological Damage: From Acute Stage to Post-Acute Sequelae of COVID-19. Zingaropoli MA; Pasculli P; Barbato C; Petrella C; Fiore M; Dominelli F; Latronico T; Ciccone F; Antonacci M; Liuzzi GM; Talarico G; Bruno G; Galardo G; Pugliese F; Lichtner M; Mastroianni CM; Minni A; Ciardi MR Cells; 2023 Sep; 12(18):. PubMed ID: 37759493 [No Abstract] [Full Text] [Related]
35. Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity. Virhammar J; Nääs A; Fällmar D; Cunningham JL; Klang A; Ashton NJ; Jackmann S; Westman G; Frithiof R; Blennow K; Zetterberg H; Kumlien E; Rostami E Eur J Neurol; 2021 Oct; 28(10):3324-3331. PubMed ID: 33369818 [TBL] [Abstract][Full Text] [Related]
36. Neurofilament light chain and MRI volume parameters as markers of neurodegeneration in multiple sclerosis. Filippi P; Vestenická V; Siarnik P; Sivakova M; Čopíková-Cudráková D; Belan V; Hanes J; Novák M; Kollar B; Turcani P Neuro Endocrinol Lett; 2020 Apr; 41(1):17-26. PubMed ID: 32338853 [TBL] [Abstract][Full Text] [Related]
37. Neurofilament Light Chain Levels Are Associated with Disease Activity Determined by No Evident Disease Activity in Multiple Sclerosis Patients. Szilasiová J; Rosenberger J; Fedičová M; Mikula P; Urban P; Gdovinová Z; Vitková M; Hanes J; Stevens E Eur Neurol; 2021; 84(4):272-279. PubMed ID: 34034261 [TBL] [Abstract][Full Text] [Related]
38. Symptoms Compatible With Long Coronavirus Disease (COVID) in Healthcare Workers With and Without Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection-Results of a Prospective Multicenter Cohort. Strahm C; Seneghini M; Güsewell S; Egger T; Leal-Neto O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Ruetti M; Rutz R; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; Kuster SP; McGeer A; Risch L; Friedl A; Schlegel M; Schmid D; Vernazza P; Kahlert CR; Kohler P Clin Infect Dis; 2022 Aug; 75(1):e1011-e1019. PubMed ID: 35090015 [TBL] [Abstract][Full Text] [Related]
39. Plasma and CSF Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Cross-Sectional and Longitudinal Study. Vacchiano V; Mastrangelo A; Zenesini C; Masullo M; Quadalti C; Avoni P; Polischi B; Cherici A; Capellari S; Salvi F; Liguori R; Parchi P Front Aging Neurosci; 2021; 13():753242. PubMed ID: 34744694 [No Abstract] [Full Text] [Related]
40. Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials. Leppert D; Kropshofer H; Häring DA; Dahlke F; Patil A; Meinert R; Tomic D; Kappos L; Kuhle J Neurology; 2022 May; 98(21):e2120-e2131. PubMed ID: 35379762 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]